Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan

Human Vaccines

Volumn 3, Issue 4, 2007, Pages 135-138

  Flitter, Becca A ^a   Ismail, Adil ^b   Vu, David ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b Ministry of Health   (Sudan)

Author keywords

Bactericidal activity; Neisseria meningitidis; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORTH AMERICA; SCHOOL CHILD; SUDAN; VACCINATION;

EID: 34848815016     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.4.4308     Document Type: Article

References (30)

1. Greenwood B. Manson Lecture: Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999; 93:341-53.
2. Greenwood BM, Whittle HC, Bradley AK, Fayet MT, Gilles HM. The duration of the antibody response to meningococcal vaccination in an African village. Trans R Soc Trop Med Hyg 1980; 74:756-60.
3. Mohammed I, Obineche EN, Onyemelukwe GC, Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria. J Infect 1984; 9:190-6.
4. Ismail AA, Harris SL, Granoff DM. Serum group A anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr Infect Dis J 2004; 23:748-55.
5. Harris SL, King WJ, Ferris W, Granoff DM. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun 2003; 71:275-86.
6. Welsch JA, Granoff D. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun 2004; 72:5903-9.
7. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129:1327-48.
8. Granoff D, Feavers I, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: W. B. Saunders Company, 2003.
9. Wahdan MH, Sallam SA, Hassan MN, Abdel Gawad A, Rakha AS, Sippel JE, Hablas R, Sanborn WR, Kassem NM, Riad SM, Cvjetanovic B. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ 1977; 55:645-51.
10. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, Jones EE, Phillips C, Tiendrebeogo H, Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2:114-8.
11. Zangwill KM, Stout RW, Carlone GM, Pais L, Harekeh H, Mitchell S, Wolfe WH, Blackwood V, Plikaytis BD, Wenger JD. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994; 169:847-52.
12. Mohammed I, Onyemelukwe GC, Obineche EN, Gupta N, Oyeyinka GO. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination. J Infect 1984; 9:197-202.
13. Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, Sivonen A, Renkonen OV, Pettay O, Karanko V, Ahvonen P, Sarna S. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297:686-91.
14. Makela PH, Kayhty H, Weckstrom P, Sivonen A, Renkonen OV. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975; 2:883-6.
15. Maslanka SE, Tappero JW, Plikaytis BD, Brumberg RS, Dykes JK, Gheesling LL, Donaldson KB, Schuchat A, Pullman J, Jones M, Bushmaker J, Carlone GM. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998; 66:2453-9.
16. Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998; 5:479-85.
17. Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2005; 24:132-6.
18. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2004; 23:490-7.
19. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24:5093-107.
20. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect Immun 2001; 69:1568-73.
21. Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000; 28:193-7.
22. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8:616-23.
23. Dull PM, Abdelwahab J, Sacchi CT, Becker M, Noble CA, Barnett GA, Kaiser RM, Mayer LW, Whitney AM, Schmink S, Ajello GW, Dolan-Livengood J, Stephens DS, Cetron MS, Popovic T, Rosenstein NE. Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. J Infect Dis 2005; 191:33-9.
24. Kellerman SE, McCombs K, Ray M, Baughman W, Reeves MW, Popovic T, Rosenstein NE, Farley MM, Blake P, Stephens DS. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis 2002; 186:40-8.
25. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894-901.
26. Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001; 19:4566-75.
27. Bilukha OO, Rosenstein N. Centers for disease control and prevention: Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2005; 54:1-21.
28. Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine 2005; 23:977-83.
29. Ceesay SJ, Allen SJ, Menon A, Todd JE, Cham K, Carlone GM, Turner SH, Gheesling LL, DeWitt W, Plikaytis BD, et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993; 167:1212-6.
30. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13.